AnaptysBio Stock Surges: Rosnilimab Shows Promise in RA Treatment

Anaptysbio, Inc. rose 6.29% in premarket trading, driven by positive updates on its rosnilimab data. The company reported favorable safety and tolerability profiles, as well as durable responses for at least two months off drug, with potential for extended dosing intervals in the maintenance setting. These updates suggest a promising outlook for the company's Phase 2b trial for rheumatoid arthritis.